US Patent

US8410131 — Cancer treatment

Method of Use · Assigned to Novartis Pharmaceuticals Corp · Expires 2025-11-01 · 1y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.

USPTO Abstract

Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.

Drugs covered by this patent

Afinitor (everolimus) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1368`	—	Afinitor
`U-1368`	—	Afinitor
`U-1368`	—	Afinitor
`U-1368`	—	Afinitor

Patent Metadata

Patent number: US8410131
Jurisdiction: US
Classification: Method of Use
Expires: 2025-11-01
Drug substance claim: No
Drug product claim: No
Assignee: Novartis Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.